Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 3 treatment practicalities and recommendations. MS Neurology Group of the Australian and New Zealand Association of Neurologists

• Published in: Journal of clinical neuroscience 2014-11, Vol.21 (11), p.1857-1865
• Main Authors: Broadley, Simon A, Barnett, Michael H, Boggild, Mike, Brew, Bruce J, Butzkueven, Helmut, Heard, Robert, Hodgkinson, Suzanne, Kermode, Allan G, Lechner-Scott, Jeannette, Macdonell, Richard A L, Marriott, Mark, Mason, Deborah F, Parratt, John, Reddel, Stephen W, Shaw, Cameron P, Slee, Mark, Spies, Judith, Taylor, Bruce V, Carroll, William M, Kilpatrick, Trevor J, King, John, McCombe, Pamela A, Pollard, John D, Willoughby, Ernest
• Format: Article
• Language: English
• Subjects: Adult; Antibodies, Monoclonal, Humanized - adverse effects; Antibodies, Monoclonal, Humanized - immunology; Antibodies, Monoclonal, Humanized - therapeutic use; Australia - epidemiology; Disease Management; Disease Progression; Drug Monitoring; Drug Substitution; Drug-Related Side Effects and Adverse Reactions - etiology; Drug-Related Side Effects and Adverse Reactions - prevention & control; Evidence-Based Medicine; Female; Forecasting; Humans; Immunosuppressive Agents - adverse effects; Immunosuppressive Agents - therapeutic use; Interferon-beta - immunology; Interferon-beta - therapeutic use; JC Virus - immunology; JC Virus - isolation & purification; Lactation; Leukoencephalopathy, Progressive Multifocal - prevention & control; Male; Multiple Sclerosis - drug therapy; Multiple Sclerosis - epidemiology; Multiple Sclerosis - pathology; Multiple Sclerosis - therapy; Natalizumab; Neutralization Tests; New Zealand - epidemiology; Pregnancy; Pregnancy Complications - drug therapy; Therapies, Investigational - trends; Treatment Outcome
• ISSN: 1532-2653
• DOI: 10.1016/j.jocn.2014.01.017

In this third and final part of our review of multiple sclerosis (MS) treatment we look at the practical day-to-day management issues that are likely to influence individual treatment decisions. Whilst efficacy is clearly of considerable importance, tolerability and the potential for adverse effects often play a significant role in informing individual patient decisions. Here we review the issues surrounding switching between therapies, and the evidence to assist guiding the choice of therapy to change to and when to change. We review the current level of evidence with regards to the management of women in their child-bearing years with regards to recommendations about treatment during pregnancy and whilst breast feeding. We provide a summary of recommended pre- and post-treatment monitoring for the available therapies and review the evidence with regards to the value of testing for antibodies which are known to be neutralising for some therapies. We review the occurrence of adverse events, both the more common and troublesome effects and those that are less common but have potentially much more serious outcomes. Ways of mitigating these risks and managing the more troublesome adverse effects are also reviewed. Finally, we make specific recommendations with regards to the treatment of MS. It is an exciting time in the world of MS neurology and the prospects for further advances in coming years are high.